B-cell dyscrasias are disorders of the plasma cells, characterised by the abnormal proliferation of a monoclonal population of plasma cells that may or may not secrete detectable levels of a monoclonal immunoglobulin or immunoglobulin fragment (paraprotein or M protein).
This group includes multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma of bone, extramedullary plasmacytoma, Waldenström’s macroglobulinemia (WM), primary amyloidosis, light chain deposition disease, paraproteinemia, and heavy-chain disease.
Abingdon Health is addressing unmet clinical needs in this area with the introduction of rapid and near patient tests for diagnosis and monitoring of B-cell dyscrasias. The first product to market is Seralite® – FLC, a device for the quantitative analysis of free light chains.
Several #job vacancies: ✅R&D Scientist ✅Technical Transfer Scientist ✅Quality Control Supervisor ✅Quality Control… https://t.co/KgK0XS6Hdf
21 March 2019
© Abingdon Health 2019